Meiji Seika Pharma to unveil two ophthalmic products in Indonesia under an agreement with Santen Pharmaceutical.
M2 PHARMA-August 7, 2019-Meiji Seika Pharma to unveil two ophthalmic products in Indonesia under an agreement with Santen Pharmaceutical
(C)2019 M2 COMMUNICATIONS
Healthcare company Meiji Seika Pharma Co Ltd revealed on Tuesday the availability of DIQUAS ophthalmic solution 3% (Diquafosol Sodium) and TAFLOTAN ophthalmic solution 0.0015% (Tafluprost) in Indonesia.
The company has launched the two products in Indonesia under an agreement with Santen Pharmaceutical Co Ltd.
Santen's IQUAS ophthalmic solution 3% (Diquafosol Sodium) is used for the treatment of dry-eye and TAFLOTAN ophthalmic solution 0.0015% (Tafluprost) Glaucoma is used for the treatment of ocular hypertension.
Based on the working business agreement with Santen, these products will be marketed in Indonesia by Meiji's affiliated subsidiary, PT Meiji Indonesian Pharmaceutical Industries,which has established a new marketing team specialized on ophthalmic treatments and Santen will support their marketing activities.
In conjunction, PT Meiji and Santen will work together to expand market share in Indonesia for ophthalmic products.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Date:||Aug 7, 2019|
|Previous Article:||HCL Technologies collaborates with Oracle Health Sciences.|
|Next Article:||Evox Therapeutics awarded key exosome patents in the US and Europe.|